Portal de Periódicos da CAPES

A Controlled Trial of a Human Papillomavirus Type 16 Vaccine

2002; Massachusetts Medical Society; Volume: 347; Issue: 21 Linguagem: Inglês

10.1056/nejmoa020586

1533-4406

Laura A. Koutsky, Kevin A. Ault, Cosette M. Wheeler, Darron R. Brown, Eliav Barr, Frances B. Alvarez, Lisa M. Chiacchierini, Kathrin U. Jansen,

Hepatitis B Virus Studies

Approximately 20 percent of adults become infected with human papillomavirus type 16 (HPV-16). Although most infections are benign, some progress to anogenital cancer. A vaccine that reduces the incidence of HPV-16 infection may provide important public health benefits.